Grosjean Félix, Shaldaeva Maria, Cros-Perrial Emeline, Rodriguez Céline, Ghoteimi Rayane, Lebrun Aurélien, Gao Zhan-Guo, Uttaro Jean-Pierre, Mathé Christophe, Jacobson Kenneth A, Petter Jordheim Lars, Ménétrier-Caux Christine, Chaloin Laurent, Peyrottes Suzanne
Institut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard, Univ. Montpellier, CNRS, ENSCM, 34293, Montpellier, France.
Institut de Recherche en Infectiologie de Montpellier (IRIM), Univ. Montpellier, CNRS, 34293, Montpellier, France.
ChemMedChem. 2025 Mar 15;20(6):e202400662. doi: 10.1002/cmdc.202400662. Epub 2025 Jan 2.
Various series of 4,6-disubstituted-2-thiopyridine derivatives were synthesized and evaluated as potential ecto-5'-nucleotidase (CD73) inhibitors. Altogether, about ninety compounds were prepared using a general synthetic pathway involving one or two steps (eventually one-pot) procedures. Variation of the nature of the substituents in positions 4 and 6 (methyl, trifluoromethyl or phenyl) of the thiopurine ring, as well as on the thiol function, was examined and led to marked differences both in term of reactivity and ability to interfere with the putative target protein. Using a functional assay on immune cells, few compounds belonging to series 4 were shown to be able to antagonize the inhibition of the T-cell proliferation at both 100 μM and 10 μM (completely for 4 ab and partially for 4 ai), that is as potent as AOPCP which entirely reversed the inhibitory impact of exogenous ATP on T cell proliferation until 62.5 μM. In addition, we have shown that both compounds (4 ab and 4 ai) were also capable of moderately inhibiting the hA receptor with Ki in the μmolar range in HEK-293 cells. Thus, with the aim to reduce the molecular size and the lipophilicity of our initial scaffold, we finally observed by serendipity a modification of the potential target of our compounds.
合成了各种系列的4,6-二取代-2-硫代吡啶衍生物,并将其作为潜在的胞外5'-核苷酸酶(CD73)抑制剂进行评估。总共使用涉及一步或两步(最终一锅法)程序的通用合成途径制备了约90种化合物。研究了硫嘌呤环4位和6位(甲基、三氟甲基或苯基)以及硫醇官能团上取代基性质的变化,这导致了反应性和干扰假定靶蛋白能力方面的显著差异。通过对免疫细胞进行功能测定,发现4系列中的少数化合物在100 μM和10 μM时能够拮抗T细胞增殖的抑制作用(4 ab完全拮抗,4 ai部分拮抗),其效力与AOPCP相当,AOPCP可完全逆转外源性ATP对T细胞增殖的抑制作用直至62.5 μM。此外,我们还表明这两种化合物( 4 ab和4 ai)在HEK-293细胞中也能够以微摩尔范围内的Ki值适度抑制hA受体。因此,为了减小我们初始支架的分子大小和亲脂性,我们最终偶然观察到了我们化合物潜在靶点的一种修饰。